- Home
- DTIL vs ICCM Comparison
DTIL vs ICCM Comparison
Compare DTIL & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DTIL | ICCM |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.8M | 43.4M |
| IPO Year | 2019 | 2013 |
Fundamental Metrics
Financial Performance| Metric | DTIL | ICCM |
|---|---|---|
| Price | $6.38 | $0.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $60.00 | $2.50 |
| AVG Volume (30 Days) | ★ 188.7K | 180.6K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,070,000,000.00 | N/A |
| Revenue This Year | N/A | $19.87 |
| Revenue Next Year | $48.47 | $31.38 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.53 | $0.54 |
| 52 Week High | $8.82 | $1.52 |
Technical Indicators
Market Signals| Indicator | DTIL | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 80.70 | 68.80 |
| Support Level | $4.50 | $0.68 |
| Resistance Level | $8.82 | $0.74 |
| Average True Range (ATR) | 0.43 | 0.05 |
| MACD | 0.20 | 0.01 |
| Stochastic Oscillator | 90.61 | 96.44 |
Price Performance
Historical ComparisonAbout DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.